Compare Credo Technology Group Holding Ltd (CRDO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Johnson & Johnson — how do they compare? Credo Technology Group Holding Ltd trades at $276.73 (market cap $46.19B), while Johnson & Johnson trades at $260.68 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 13.6× Credo Technology Group Holding Ltd's market cap, and Johnson & Johnson pays a 2.06% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | JNJ | |
|---|---|---|
Market Cap | $46.19B | $626.09B |
Sector | Technology | Health |
52-Week High | $302.52 | $267.24 |
52-Week Low | $87.81 | $172.78 |
Enterprise Value | $44.77B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $275.98, up 15.02% in 24 hours, reflecting strong momentum. Technical indicators show a bullish trend with support at $243 and resistance at $250. The company reported robust earnings, beating estimates in Q3 2025, Q4 2025, and Q1 2026, with revenue surging 157% year-over-year in Q4 2025. Analyst consensus is strongly bullish, with 13 buy ratings and a price target of $285.42. Recent news highlights AI infrastructure demand driving growth, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financial performance, but risks include high valuation multiples and customer concentration. The stock offers growth potential, yet investors should monitor execution risks and market volatility. Upside is supported by analyst targets, while downside protection exists near support levels.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
